Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 02 August 2018

Indication(s)

PROCYSBI is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Sleep Apnea

Sleep Apnea

Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. Learn about the two main types of sleep apnea and hear from experts as they present the latest research at the Sleep and Breathing conference (Marseille, 2019).

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/002465
Orphan designation Yes
Date First Approved 06-09-2013
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Chiesi Farmaceutici S.p.A